ILMN Illumina Inc
Company Analysis
Latest News
🟢 Illumina is trading 4.22% up today ahead of S&P 500 inclusion
Illumina is trading 4.22% up at $239.75, extending its recent rally as investors position for S&P 500 inclusion before the September 21, 2026 open. -...
🟢 Illumina is trading 4.35% up today ahead of S&P 500 inclusion
Illumina is trading 4.35% up now at $231.97, driven by continued buying ahead of its S&P 500 inclusion, effective before the September 21, 2026 open. -...
🟢 Illumina is trading 4.6% up today on upcoming S&P 500 inclusion
Illumina is trading 4.6% up at $217.78, supported by continued momentum ahead of its S&P 500 inclusion, effective before the September 21, 2026 open. - UBS...
Illumina Upgraded to Buy as UBS Nearly Doubles Price Target to $260
UBS upgraded Illumina (ILMN) from Neutral to Buy on September 9, 2026. The firm increased its price target for the stock to $260 from $135. This new target...
Triple Frond Partners Exits Entire Stake in Illumina (ILMN)
Major investor Triple Frond Partners sold its entire position in genetics sequencing leader Illumina Inc. (ILMN) during the second quarter of 2026. The firm...
🔴 Illumina falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Illumina attracts institutional buyers despite director’s $145 million stock sale
Several institutional investors recently established new positions in Illumina. Patient Capital Management LLC acquired 345,314 shares valued at approximately...
🟢 Illumina is trading 5% up today after broad biotech rally
Illumina is trading now at $215.64, up 5.19%, following investor enthusiasm after Moderna and Merck’s positive Phase 3 personalized mRNA cancer-vaccine results...
🟢 Illumina rises 5.8% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Illumina Completes $300M Public Offering of 4.950% Notes Due 2029
Illumina announced the completion of a public offering of $300 million in senior notes. The company intends to use the net proceeds, combined with cash on...
Illumina Director Sells $148 Million Stake in Year’s Largest Insider Trade
Illumina, Inc. Independent Director Keith Meister sold a block of shares worth approximately $148 million. The transaction was executed at a price of roughly...
Illumina Reaches No-Payment Settlement with Icahn in GRAIL Acquisition Lawsuit
Illumina, along with several current and former directors, has entered into a settlement agreement to dismiss the lawsuit filed by Icahn Partners LP concerning...
🔴 Illumina is trading 5% down today with no clear company-specific catalyst
Illumina is trading at $188.77 (-4.79%) after no clear company-specific catalyst emerged in August 6, 2026 coverage. • The latest confirmed company event was...
🔴 Illumina is trading 4.1% down today on profit-taking and broader biotech weakness
Illumina is trading 4.1% down at $196.74 on post-earnings profit-taking and broader biotech sector weakness. • The company beat Q2 expectations and raised its...
Illumina's second quarter revenue of $1.16B beats estimates, prompting a raised full-year 2026 outlook.
Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% year-over-year, and non-GAAP diluted EPS of $1.31. These results exceeded analyst...
🟢 Illumina is trading 4.1% up today ahead of Q2 earnings release
Illumina is trading 4.1% up at $202.76 as investors position themselves ahead of the company’s Q2 2026 earnings release scheduled for after the market...
Illumina Inc Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Illumina is projected to report Q2 2026 revenue of $1.12 billion and EPS of $1.23, as the current stock price of $128.45 seeks to close the gap toward the...
🔴 Illumina is trading 5.3% down today on broad tariff concerns and a tech-led pullback
Illumina is trading 5.3% down at $186.41 in pre-market action as markets digest new broad U.S. tariffs and a tech-led retreat. • The decline follows a...
🟢 Illumina is trading 4.08% up today as shares gain momentum following new executive appointments
Illumina is trading at $195.47 (+4.08%) today. • The company announced the appointments of Mike Sullivan as Chief Commercial Officer and Julie Coletti as...
🔴 ILMN is trading 5.2% down today on a post-earnings pullback following a recent guidance-driven surge
ILMN is trading 5.2% down at $181.71 in pre-market as investors reassess the stock's valuation following a significant rally triggered by its latest financial...